Transdermal buprenorphine for acute postoperative pain: a systematic review

Abstract Background and objectives: Postoperative pain is still a major concern in several surgical procedures. Multimodal analgesia is best for postoperative pain management; however, opioid therapy is still the main treatment for pain after surgical procedures. Transdermal buprenorphine is a partial µ-agonist opioid widely used for chronic pain syndromes, with limited evidence for acute postoperative pain. A systematic review of studies examining transdermal buprenorphine for acute pain management after surgery was conducted. Contents: Data from PubMed, Embase, The Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL via EBSCOhost, and LILACS were reviewed, including randomized clinical trials that evaluated total postoperative pain, postoperative analgesic consumption, drug-related side effects and patient satisfaction with analgesia regimen. Data from nine studies (615 patients) were included in this review. Most studies initiated transdermal buprenorphine use 6 to 48 hours before surgery, maintaining use from 1 to 28 days after the procedure. Most studies showed lower or similar postoperative pain scores, postoperative analgesic consumption and patient satisfaction comparing buprenorphine to placebo, tramadol, celecoxib, flurbiprofen and parecoxib. The incidence of side effects varied between studies, with most showing no increase in drug-related side effects with buprenorphine use, except one study, which compared buprenorphine to oral tramadol, and one to transdermal fentanyl. However, most results were derived from evidence with an overall high or unclear risk of bias. Conclusions: Although more studies are necessary, initial results show that transdermal buprenorphine seems to be an effective and safe opioid choice for management of acute postoperative pain.

Saved in:
Bibliographic Details
Main Authors: Machado,Felipe Chiodini, Carone Neto,Gilson, Paiva,Luisa Oliveira de, Soares,Tamiris Cristina, Nakamura,Ricardo Kenithi, Nascimento,Leonardo de Freitas, Campana,Camila Sato, Lustosa,Lia Alves Martins Mota, Cortez,Rachel Andrade, Ashmawi,Hazem Adel
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Anestesiologia 2020
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-70942020000400419
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0034-70942020000400419
record_format ojs
spelling oai:scielo:S0034-709420200004004192020-10-22Transdermal buprenorphine for acute postoperative pain: a systematic reviewMachado,Felipe ChiodiniCarone Neto,GilsonPaiva,Luisa Oliveira deSoares,Tamiris CristinaNakamura,Ricardo KenithiNascimento,Leonardo de FreitasCampana,Camila SatoLustosa,Lia Alves Martins MotaCortez,Rachel AndradeAshmawi,Hazem Adel Buprenorphine Cutaneous administration Transdermal patch Postoperative pain Acute pain Abstract Background and objectives: Postoperative pain is still a major concern in several surgical procedures. Multimodal analgesia is best for postoperative pain management; however, opioid therapy is still the main treatment for pain after surgical procedures. Transdermal buprenorphine is a partial µ-agonist opioid widely used for chronic pain syndromes, with limited evidence for acute postoperative pain. A systematic review of studies examining transdermal buprenorphine for acute pain management after surgery was conducted. Contents: Data from PubMed, Embase, The Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL via EBSCOhost, and LILACS were reviewed, including randomized clinical trials that evaluated total postoperative pain, postoperative analgesic consumption, drug-related side effects and patient satisfaction with analgesia regimen. Data from nine studies (615 patients) were included in this review. Most studies initiated transdermal buprenorphine use 6 to 48 hours before surgery, maintaining use from 1 to 28 days after the procedure. Most studies showed lower or similar postoperative pain scores, postoperative analgesic consumption and patient satisfaction comparing buprenorphine to placebo, tramadol, celecoxib, flurbiprofen and parecoxib. The incidence of side effects varied between studies, with most showing no increase in drug-related side effects with buprenorphine use, except one study, which compared buprenorphine to oral tramadol, and one to transdermal fentanyl. However, most results were derived from evidence with an overall high or unclear risk of bias. Conclusions: Although more studies are necessary, initial results show that transdermal buprenorphine seems to be an effective and safe opioid choice for management of acute postoperative pain.info:eu-repo/semantics/openAccessSociedade Brasileira de AnestesiologiaRevista Brasileira de Anestesiologia v.70 n.4 20202020-08-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-70942020000400419en10.1016/j.bjane.2020.06.009
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Machado,Felipe Chiodini
Carone Neto,Gilson
Paiva,Luisa Oliveira de
Soares,Tamiris Cristina
Nakamura,Ricardo Kenithi
Nascimento,Leonardo de Freitas
Campana,Camila Sato
Lustosa,Lia Alves Martins Mota
Cortez,Rachel Andrade
Ashmawi,Hazem Adel
spellingShingle Machado,Felipe Chiodini
Carone Neto,Gilson
Paiva,Luisa Oliveira de
Soares,Tamiris Cristina
Nakamura,Ricardo Kenithi
Nascimento,Leonardo de Freitas
Campana,Camila Sato
Lustosa,Lia Alves Martins Mota
Cortez,Rachel Andrade
Ashmawi,Hazem Adel
Transdermal buprenorphine for acute postoperative pain: a systematic review
author_facet Machado,Felipe Chiodini
Carone Neto,Gilson
Paiva,Luisa Oliveira de
Soares,Tamiris Cristina
Nakamura,Ricardo Kenithi
Nascimento,Leonardo de Freitas
Campana,Camila Sato
Lustosa,Lia Alves Martins Mota
Cortez,Rachel Andrade
Ashmawi,Hazem Adel
author_sort Machado,Felipe Chiodini
title Transdermal buprenorphine for acute postoperative pain: a systematic review
title_short Transdermal buprenorphine for acute postoperative pain: a systematic review
title_full Transdermal buprenorphine for acute postoperative pain: a systematic review
title_fullStr Transdermal buprenorphine for acute postoperative pain: a systematic review
title_full_unstemmed Transdermal buprenorphine for acute postoperative pain: a systematic review
title_sort transdermal buprenorphine for acute postoperative pain: a systematic review
description Abstract Background and objectives: Postoperative pain is still a major concern in several surgical procedures. Multimodal analgesia is best for postoperative pain management; however, opioid therapy is still the main treatment for pain after surgical procedures. Transdermal buprenorphine is a partial µ-agonist opioid widely used for chronic pain syndromes, with limited evidence for acute postoperative pain. A systematic review of studies examining transdermal buprenorphine for acute pain management after surgery was conducted. Contents: Data from PubMed, Embase, The Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL via EBSCOhost, and LILACS were reviewed, including randomized clinical trials that evaluated total postoperative pain, postoperative analgesic consumption, drug-related side effects and patient satisfaction with analgesia regimen. Data from nine studies (615 patients) were included in this review. Most studies initiated transdermal buprenorphine use 6 to 48 hours before surgery, maintaining use from 1 to 28 days after the procedure. Most studies showed lower or similar postoperative pain scores, postoperative analgesic consumption and patient satisfaction comparing buprenorphine to placebo, tramadol, celecoxib, flurbiprofen and parecoxib. The incidence of side effects varied between studies, with most showing no increase in drug-related side effects with buprenorphine use, except one study, which compared buprenorphine to oral tramadol, and one to transdermal fentanyl. However, most results were derived from evidence with an overall high or unclear risk of bias. Conclusions: Although more studies are necessary, initial results show that transdermal buprenorphine seems to be an effective and safe opioid choice for management of acute postoperative pain.
publisher Sociedade Brasileira de Anestesiologia
publishDate 2020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0034-70942020000400419
work_keys_str_mv AT machadofelipechiodini transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT caronenetogilson transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT paivaluisaoliveirade transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT soarestamiriscristina transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT nakamuraricardokenithi transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT nascimentoleonardodefreitas transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT campanacamilasato transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT lustosaliaalvesmartinsmota transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT cortezrachelandrade transdermalbuprenorphineforacutepostoperativepainasystematicreview
AT ashmawihazemadel transdermalbuprenorphineforacutepostoperativepainasystematicreview
_version_ 1756376401781456896